Filing Details

Accession Number:
0000899243-18-020533
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-24 19:15:51
Reporting Period:
2018-07-23
Accepted Time:
2018-07-24 19:15:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434418 Constellation Pharmaceuticals Inc CNST () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1192595 I Robert Tepper C/O Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge MA 02142
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-23 2,705,334 $0.00 2,716,384 No 4 C Indirect By Funds
Common Stock Acquisiton 2018-07-23 266,667 $15.00 2,983,051 No 4 P Indirect By Funds
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Funds
No 4 P Indirect By Funds
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2018-07-23 11,000,000 $0.00 999,180 $0.00
Common Stock Series B Preferred Stock Disposition 2018-07-23 10,650,000 $0.00 967,389 $0.00
Common Stock Series D Preferred Stock Disposition 2018-07-23 1,086,411 $0.00 98,683 $0.00
Common Stock Series E Preferred Stock Disposition 2018-07-23 2,285,640 $0.00 266,934 $0.00
Common Stock Series E-1 Preferred Stock Disposition 2018-07-23 3,107,930 $0.00 282,308 $0.00
Common Stock Series F Preferred Stock Disposition 2018-07-23 1,000,000 $0.00 90,840 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
  2. These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). Dr. Tepper is an individual manager of TRV GP LLC. Dr. Tepper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.